美国药品NDC(国家药品编码)与药品说明书数据库(U.S. FDA National Drug Code DataBase)
检索条件:" 注册申请号=NDA212614"
NDC包装代码 产品NDC 产品类型 商品名 通用名 剂型 给药途径 上市日期 结束日期 市场类别 申请号 标签持有者 活性成分 规格 包装描述
0597-0390-13 0597-0390 HUMAN PRESCRIPTION DRUG Trijardy XR empagliflozin, linagliptin, metformin hydrochloride TABLET, EXTENDED RELEASE ORAL 20200423 N/A NDA NDA212614 Boehringer Ingelheim Pharmaceuticals, Inc. EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE 25 mg/1; 5 mg/1; 1000 mg/1 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0390-13)
0597-0390-31 0597-0390 HUMAN PRESCRIPTION DRUG Trijardy XR empagliflozin, linagliptin, metformin hydrochloride TABLET, EXTENDED RELEASE ORAL 20200423 N/A NDA NDA212614 Boehringer Ingelheim Pharmaceuticals, Inc. EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE 25 mg/1; 5 mg/1; 1000 mg/1 1 BOTTLE in 1 CARTON (0597-0390-31) / 7 TABLET, EXTENDED RELEASE in 1 BOTTLE
0597-0390-71 0597-0390 HUMAN PRESCRIPTION DRUG Trijardy XR empagliflozin, linagliptin, metformin hydrochloride TABLET, EXTENDED RELEASE ORAL 20200423 N/A NDA NDA212614 Boehringer Ingelheim Pharmaceuticals, Inc. EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE 25 mg/1; 5 mg/1; 1000 mg/1 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0390-71)
0597-0385-77 0597-0385 HUMAN PRESCRIPTION DRUG Trijardy XR empagliflozin, linagliptin, metformin hydrochloride TABLET, EXTENDED RELEASE ORAL 20200423 N/A NDA NDA212614 Boehringer Ingelheim Pharmaceuticals, Inc. EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE 12.5 mg/1; 2.5 mg/1; 1000 mg/1 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0385-77)
0597-0385-86 0597-0385 HUMAN PRESCRIPTION DRUG Trijardy XR empagliflozin, linagliptin, metformin hydrochloride TABLET, EXTENDED RELEASE ORAL 20200423 N/A NDA NDA212614 Boehringer Ingelheim Pharmaceuticals, Inc. EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE 12.5 mg/1; 2.5 mg/1; 1000 mg/1 180 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0385-86)
0597-0385-88 0597-0385 HUMAN PRESCRIPTION DRUG Trijardy XR empagliflozin, linagliptin, metformin hydrochloride TABLET, EXTENDED RELEASE ORAL 20200423 N/A NDA NDA212614 Boehringer Ingelheim Pharmaceuticals, Inc. EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE 12.5 mg/1; 2.5 mg/1; 1000 mg/1 1 BOTTLE in 1 CARTON (0597-0385-88) / 14 TABLET, EXTENDED RELEASE in 1 BOTTLE
0597-0380-13 0597-0380 HUMAN PRESCRIPTION DRUG Trijardy XR empagliflozin, linagliptin, metformin hydrochloride TABLET, EXTENDED RELEASE ORAL 20200423 N/A NDA NDA212614 Boehringer Ingelheim Pharmaceuticals, Inc. EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE 10 mg/1; 5 mg/1; 1000 mg/1 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0380-13)
0597-0380-68 0597-0380 HUMAN PRESCRIPTION DRUG Trijardy XR empagliflozin, linagliptin, metformin hydrochloride TABLET, EXTENDED RELEASE ORAL 20200423 N/A NDA NDA212614 Boehringer Ingelheim Pharmaceuticals, Inc. EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE 10 mg/1; 5 mg/1; 1000 mg/1 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0380-68)
0597-0395-82 0597-0395 HUMAN PRESCRIPTION DRUG Trijardy XR empagliflozin, linagliptin, metformin hydrochloride TABLET, EXTENDED RELEASE ORAL 20200423 N/A NDA NDA212614 Boehringer Ingelheim Pharmaceuticals, Inc. EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE 5 mg/1; 2.5 mg/1; 1000 mg/1 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0395-82)
0597-0395-23 0597-0395 HUMAN PRESCRIPTION DRUG Trijardy XR empagliflozin, linagliptin, metformin hydrochloride TABLET, EXTENDED RELEASE ORAL 20200423 N/A NDA NDA212614 Boehringer Ingelheim Pharmaceuticals, Inc. EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE 5 mg/1; 2.5 mg/1; 1000 mg/1 180 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0395-23)
商品名称,通用名称,活性成分名称,申请号搜索 高级检索
©2006-2024 Drugfuture->U.S. FDA National Drug Code DataBase